text: Data analyzed was from a phase III , randomized clinical trial of DOX ( 60 mg/m ( 2 ) every 3 weeks ) or PLD ( 50 mg/m ( 2 ) every 4 weeks ) for the first line therapy for MBC ( n = 509 ) ( O'Brien et al , Ann Oncol .
entities.text: DOX
entities.type: intervention
entities.text: PLD
entities.type: intervention
entities.text: MBC ( n = 509 )
entities.type: participant